CagriSema Significantly Lowers Blood Pressure in Adults with Overweight or Obesity
Background
The global prevalence of overweight and obesity continues to rise, posing a significant public health challenge. These conditions are strongly associated with numerous co-morbidities, including hypertension (high blood pressure), which is a leading risk factor for cardiovascular disease. While weight loss is known to improve blood pressure, the direct impact of novel, highly effective weight management pharmacotherapies on cardiovascular risk factors is crucial. This study specifically addresses whether the dual-agonist CagriSema can effectively reduce blood pressure in individuals with overweight or obesity, thereby mitigating associated cardiovascular risks.
Results
The study demonstrated a significant and clinically meaningful reduction in blood pressure with CagriSema treatment. Participants receiving CagriSema experienced a mean reduction in systolic blood pressure (SBP) of 12.8 mmHg (95% CI: -14.1 to -11.5) from baseline, compared to a modest 2.1 mmHg reduction (95% CI: -3.0 to -1.2) in the placebo group. This resulted in a statistically significant treatment difference of -10.7 mmHg (p<0.001). Similarly, diastolic blood pressure (DBP) was reduced by 7.9 mmHg with CagriSema, versus 1.6 mmHg with placebo, yielding a difference of -6.3 mmHg (p<0.001). These blood pressure improvements were accompanied by a substantial mean body weight reduction of 19.2% in the CagriSema group, compared to 2.5% in the placebo group (p<0.001). > A significantly higher proportion of participants treated with CagriSema achieved normotensive SBP (<130 mmHg) at week 32 (68% vs 28% for placebo, p<0.001), indicating robust blood pressure control. The safety profile was consistent with known GLP-1 receptor agonists, primarily involving mild to moderate gastrointestinal adverse events.
Why It Matters
This study provides compelling evidence that CagriSema not only facilitates significant weight loss but also directly and substantially improves blood pressure in individuals with overweight or obesity and hypertension. This dual benefit is critical, as it addresses multiple interconnected cardiometabolic risk factors simultaneously, potentially leading to a greater reduction in overall cardiovascular morbidity and mortality. These findings strongly support the continued development of CagriSema as a comprehensive therapeutic option for individuals seeking effective weight management and improved cardiovascular health. The positive outcomes from REDEFINE 1 pave the way for larger Phase 3 clinical trials to further confirm these benefits and assess long-term cardiovascular outcomes, ultimately aiming for regulatory approval and widespread clinical use.